For ophthalmic use only. After instilling the drops, apply gentle pressure to the nasolacrimal duct for 1-2 minutes to minimize systemic absorption.

Tropicamide is an anticholinergic agent that blocks the muscarinic acetylcholine receptors in the sphincter pupillae muscle and ciliary body, leading to pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). Phenylephrine is an alpha-1 adrenergic agonist that directly stimulates alpha-adrenergic receptors in the dilator pupillae muscle, causing mydriasis, and in the conjunctival blood vessels, causing vasoconstriction.

• •Hypersensitivity to tropicamide, phenylephrine, or any component of the formulation.
• •Primary glaucoma or a tendency towards narrow-angle glaucoma (angle closure glaucoma).
• •Patients with cardiac disease, hypertension, or hyperthyroidism (due to phenylephrine).
• •Infants and small children (due to higher risk of systemic side effects).

Store below 30°C in a cool, dry place, away from direct sunlight. Do not freeze.

Systemic overdose is rare with ophthalmic use but may manifest as tachycardia, hypertension, headache, central nervous system effects (e.g., confusion, hallucinations, seizures), and respiratory depression. Treatment is symptomatic and supportive, including gastric lavage if ingested, and alpha-blockers for severe hypertension.

Use during pregnancy and lactation only if clearly needed and the potential benefits outweigh the potential risks. Systemic absorption is minimal, but caution is advised.